1. A composition comprising i) a construct comprising an Aβ1-6 peptide attached to a virus-like particle and ii) a pharmaceutically acceptable adjuvant. 2. The composition according to claim 1, comprising from 5 to 600 μg of the construct containing the Aβ1-6.3 peptide. The composition according to claims 1 and 2, comprising 150 μg or 450 μg of a construct containing the Aβ1-6.4 peptide. The composition according to claim 1 or 2, wherein the construct containing the Aβ1-6 peptide is in an aqueous solution. The composition of claim 1 or 2, wherein the construct comprising the Aβ1-6 peptide comprises a virus-like particle structure (VLP) covalently linked to the Aβ1-6.6 peptide. The composition according to claim 5, wherein the VLP includes RNA of the bacteriophage Qβ, the Aβ1-6 peptide is covalently attached by the C-terminal fragment to the GGC spacer sequence, and the VLP is covalently linked to the indicated Aβ1-6 peptide via a divalent linker group. A vaccine containing a composition according to any one of the preceding paragraphs. 8. The vaccine according to claim 7, wherein the adjuvant is an aluminum salt or MF59.9. The vaccine of claim 8, wherein the aluminum salt is Al (OH). 10. The vaccine of claim 8, wherein the vaccine composition contains from about 100 μl to about 500 μl of MF59 in a dose. The vaccine of claim 10, wherein the vaccine composition contains approximately 125 μl or approximately 250 μl of MF59 per dose. The vaccine of claim 8 or 9, wherein the vaccine composition contains from about 50 μg to about 850 μg of aluminum salt per dose. The vaccine of claim 12, wherein the vaccine composition contains about 50 μg, about 150 μg, about 450 μg, about 600 μg, or about 850 μg of aluminum salt per dose. A vaccine according to any one of claims 7 to 9, containing per dose: (i) approximately 150 μg of a construct containing Aβ1-6 peptide and approximately 150 μg of aluminum salt, (ii)1. Композиция, включающая i) конструкт, содержащий пептид Аβ1-6, присо
